FDA blasts California firm for multiple GLP issues involving nonclinical studies
Regulatory NewsJoanne S. Eglovitch
Audit/FDA InspectionBiologicsEthicsNorth AmericaPreclinical studyRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchAudit/FDA InspectionBiologicsEthicsNorth AmericaPreclinical studyRegulatory Intelligence/Policy